BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Tobias J, Garner-Spitzer E, Drinić M, Wiedermann U. Vaccination against Her-2/neu, with focus on peptide-based vaccines. ESMO Open 2022;7:100361. [PMID: 35026721 DOI: 10.1016/j.esmoop.2021.100361] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 3.0] [Reference Citation Analysis]
Number Citing Articles
1 Gámez-Chiachio M, Sarrió D, Moreno-Bueno G. Novel Therapies and Strategies to Overcome Resistance to Anti-HER2-Targeted Drugs. Cancers (Basel) 2022;14:4543. [PMID: 36139701 DOI: 10.3390/cancers14184543] [Reference Citation Analysis]
2 Davodabadi F, Sarhadi M, Arabpour J, Sargazi S, Rahdar A, Díez-Pascual AM. Breast cancer vaccines: New insights into immunomodulatory and nano-therapeutic approaches. J Control Release 2022;349:844-75. [PMID: 35908621 DOI: 10.1016/j.jconrel.2022.07.036] [Reference Citation Analysis]
3 Moragon S, Hernando C, Martinez-martinez MT, Tapia M, Ortega-morillo B, Lluch A, Bermejo B, Cejalvo JM. Immunological Landscape of HER-2 Positive Breast Cancer. Cancers 2022;14:3167. [DOI: 10.3390/cancers14133167] [Reference Citation Analysis]
4 Tobias J, Drinić M, Högler S, Ambroz K, Baier K, Kodajova P, Tomasich E, Berghoff AS, Schmid A, Garner-spitzer E, Kenner L, Kundi M, Zielinski CC, Wiedermann U. Active immunization with a Her-2/neu-targeting Multi-peptide B cell vaccine prevents lung metastases formation from Her-2/neu breast cancer in a mouse model. Translational Oncology 2022;19:101378. [DOI: 10.1016/j.tranon.2022.101378] [Reference Citation Analysis]